Scarica l'app Stockscreener
0.6248
0.00%
0.00
Precedente Chiudi:
$0.6248
Aprire:
$0.62
Volume 24 ore:
23,195
Relative Volume:
0.04
Capitalizzazione di mercato:
$20.53M
Reddito:
-
Utile/perdita netta:
$-55.92M
Rapporto P/E:
-0.4431
EPS:
-1.41
Flusso di cassa netto:
$-43.07M
1 W Prestazione:
-4.64%
1M Prestazione:
-18.96%
6M Prestazione:
-84.80%
1 anno Prestazione:
-72.83%
Intervallo 1D:
$0.6117
$0.62
Intervallo di 1 settimana:
$0.6107
$0.66
Portata 52W:
$0.61
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Nome
Skye Bioscience Inc
Settore
Industria
Telefono
(858) 410-0266
Indirizzo
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs PSNYW, SHMD, GOODO, DWLD, QQQE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
5.21 | 490.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
7.1347 | 412.57M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
19.91 | 372.90M | 0 | 0 | 0 | 0.00 |
DWLD
Davis Select Worldwide ETF
|
43.43 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
99.62 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-08-15 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-09-30 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-09 | Iniziato | Craig Hallum | Buy |
| 2024-05-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice - The Globe and Mail
Skye Bioscience, Inc. Files Form 8-K Announcing Notice of Delisting or Failure to Satisfy Nasdaq Continued Listing Rule (March 2026) 5 - Minichart
Skye Bioscience receives Nasdaq notice for minimum bid price deficiency By Investing.com - Investing.com India
Skye Bioscience receives Nasdaq notice for minimum bid price deficiency - Investing.com
Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Skye Bioscience (SKYE) after shares stay under $1 minimum - Stock Titan
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy - MSN
Piper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF) - The Globe and Mail
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pio - GuruFocus
Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral By Investing.com - Investing.com Canada
Citizens reiterates Skye Bioscience stock rating on weight loss data By Investing.com - Investing.com Canada
Skye Bioscience (SKYE) Advances Nimacimab Development with Promi - GuruFocus
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Hold Rating - 富途牛牛
Skye Bioscience Q4 2025 Earnings Call Transcript - MarketBeat
SKYE: Additive weight loss and durable efficacy drive nimacimab's advancement as a GLP-1 add-on - TradingView
Skye Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SKYE) 2026-03-10 - Seeking Alpha
Earnings call transcript: Skye Bioscience Q4 2025 highlights clinical advancements - Investing.com
Skye Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Skye (SKYE) Reinforces Nimacimab Strategy with Promising Data - GuruFocus
Q4 and full year results reveal momentum, Skye Bioscience, Inc. asserts - Traders Union
Skye Bioscience 2025 10-K: Net loss $(55.9M), Loss per share $(1.41) - TradingView
Skye Bioscience (NASDAQ: SKYE) highlights nimacimab obesity and metabolic pipeline - Stock Titan
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - ChartMill
Skye Bioscience Q4 2025 earnings preview - MSN
A Peek at Skye Bioscience's Future Earnings - Benzinga
Skye confirms phase 2 data on nimacimab for obesity expected later this year - MSN
Growth Value: Will Skye Bioscience Inc benefit from government policyQuarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Market Recap: Can Skye Bioscience Inc weather a recessionEarnings Growth Summary & Risk Managed Investment Strategies - baoquankhu1.vn
Growth Report: What are the analyst revisions for Skye Bioscience IncIs KNSL stock a good investment in YEARVolume Spike & Low Volatility Stock Suggestions - baoquankhu1.vn
Does Skye Bioscience Inc have a competitive edgeJuly 2025 Catalysts & Low Drawdown Momentum Ideas - baoquankhu1.vn
Smart Money: Can Skye Bioscience Inc beat the S P 5002025 Stock Rankings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Risk Report: Whats the outlook for Skye Bioscience Incs sectorJuly 2025 Closing Moves & Expert Curated Trade Ideas - baoquankhu1.vn
Skye Bioscience Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Aug Intraday: Is Skye Bioscience Inc in a bullish channelQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn
Breakout Zone: Will Skye Bioscience Inc outperform the market in YEARIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - Sahm
Why Did Skye Bioscience Stock Plummet A Whopping 60% Today? - Stocktwits
Skye Bioscience schedules March 2026 earnings release with Q4 and full-year results - Traders Union
Skye Bioscience to Release 2025 Financial Results and Business Update on March 10, 2026 - geneonline.com
Skye Bioscience : Corporate Presentation View Presentation ( 260221 Skye Corporate Presentation ) - marketscreener.com
Clinical-stage obesity biotech Skye sets March 10 results call - Stock Titan
Skye Bioscience Stock Quote, Share Price, News and Analysis - Longbridge
SKYE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Can Skye Bioscience Inc weather a recessionWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
Volume Summary: Should I hold or sell FATBP nowJuly 2025 Drop Watch & Risk Managed Investment Signals - baoquankhu1.vn
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
SKYE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SKYE Earnings History & Surprises | EPS & Revenue Results | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience says Kaitlyn Arsenault to step down as CFO effective Feb 20 - marketscreener.com
CFO exits Skye Bioscience (SKYE) with $450k severance; CEO takes accounting duties - Stock Titan
Skye Bioscience Inc Azioni (SKYE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Skye Bioscience Inc Azioni (SKYE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 22 '25 |
Sale |
3.42 |
170,449 |
582,936 |
57,493 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):